Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety
of malignant and non-malignant hematological and congenital diseases. Due to the fact that …

Transplantation of hematopoietic progenitor cells from red cell-incompatible donors occurs
in 30–50% of patients. Immediate and delayed hemolytic transfusion reactions are expected …

Background Although the AB0 blood group is one of two major antigen systems of relevance
for transplantation in humans, there are still conflicting data concerning the influence of AB0 …

Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible
hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor …

Background Haploidentical transplantation has been proposed as an effective treatment for
severe aplastic anemia (SAA). The majority of patients have more than one HLA …

BACKGROUND: The impact of donor‐recipient ABO matching on outcomes after allogeneic
stem cell transplantation has been a matter of controversy. STUDY DESIGN AND …

The impact of ABO mismatch has been studied on various hematopoietic cell transplant
(HCT) outcomes, including neutrophil and platelet engraftment, pure red cell aplasia, acute …

ABO incompatibility is not a barrier to allogeneic hematopoietic stem cell transplantation
(HSCT). However, the impact of an ABO mismatch on the outcome of the HSCT remains …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective post‐
consolidation therapy and curative option for adult patients with Philadelphia chromosome …

Background Patients receiving hematopoietic stem cell transplantation require extensive
transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable …